Alcon (ALC) announced results from time and motion studies demonstrating efficiency with Unity Vitreoretinal Cataract System for vitreoretinal and cataract surgery compared to Constellation Vision System and Centurion Vision System with Active Sentry. The studies were presented during the 25th Euretina Congress, The Retina Society’s 58th Annual Scientific Meeting and the 43rd Congress of the European Society of Cataract and Refractive Surgeons. The first study-a prospective, observational, controlled, multi-site time and motion study-used objective, videography-based measurements to directly compare Unity VCS against the Constellation Vision System in vitreoretinal surgery. Investigators assessed the duration of console set-up, intraoperative time and tear-down time of 25-gauge vitrectomy surgeries. Study results demonstrated Unity VCS provides a 16% efficiency gain in overall workflow. Unity VCS provides statistically significant efficiencies in console set-up and tear-down. The second study presented-an observational, pre-post, multi-site time and motion analysis evaluated console setup and full procedure turnover for cataract surgeries using Unity VCS with either the Intelligent Sentry handpiece or the Active Sentry handpiece, compared to the Centurion Vision System with Active Sentry handpiece. The results of the study demonstrate that Unity VCS reduces cataract surgery turnover time by 6%. In addition, reductions in total energy into the eye and ultrasound time, were observed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Alcon price target lowered to CHF 69 from CHF 80 at Deutsche Bank
- Alcon price target lowered to CHF 95 from CHF 100 at UBS
- Alcon price target lowered to CHF 80 from CHF 95 at RBC Capital
- Alcon’s Resilient Financial Strategy and Market Position Earns ‘Buy’ Rating Despite Revenue Miss